Clinical Trial Update: Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study [Phase 3]

View source ↗

Summary

Phase 3 randomized, blinded, multicenter confirmatory study of monosialoganglioside GM1 for acute ischemic stroke has completed. The sponsor is Qilu Pharmaceuti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• GM1 ganglioside (GM1 ganglioside)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Acute Ischemic Stroke | Phase 3 | Status: COMPLETED